PDF
ePub
Citation
Print
Abstract
Purpose
Twelve-core biopsy improves the detection rate of prostate cancer; however,the clinical significance of these additionally detected tumors has not been established. We retrospectively evaluated the clinical difference between prostate cancers detected by only the 12 core biopsy and by the 6 core biopsy from patients underwent radical prostatectomy.
Materials and Methods
Between February 2000 and April 2005, 124 men underwent radical prostatectomy after 12-core biopsy at Seoul National University College of Medicine, Bundang Seoul National University Hospital, Seoul National University Boramae Hospital. Among the 12-core biopsy group, we compared the subset with standard sextant cores (Group A) and the subset with lateral sextant cores (Group B). The low-risk group was defined as patients with a serum prostate-specific antigen (PSA) level less than 10.0ng/ml, a Gleason score of the final pathologic findings≤6, no pelvic lymph node metastasis and no lymphadenectomy performed, and a T stage≤T2a.
Results
There was no statistically significant difference between low-risk patients in group A and group B (p=0.0814). Groups A and B were then divided into three groups according to preoperative PSA levels of less than 10.0ng/ml, 10.0ng/ml to less than 20.0ng/ml, and greater than 20.0ng/ml. The results of the subset analysis were the same for all three PSA categories. There was no statistically significant difference when we performed the analysis between group A and group B according to the Gleason score of the final pathologic findings and the TNM stage (p=0.0814), and there was also no statistically significant difference when we performed the analysis between group A and group B according to only the Gleason score of the final pathologic findings (p=0.5026).
Figures and Tables
Table 1
Clinical characteristics of patients who underwent radical prostatectomy
A: prostate cancer was detected only at the far lateral areas (lateral apex, mid-lobe and base-7, 8, 9, 10, 11, 12 sites), B: prostate cancer was detected at including medial sites, PSA: prostate-specific antigen, Gleason score: post-operative final pathologic findings. *: statistical analysis by Student's t-test, †: statistical analysis by Fisher's exact test
Table 2
PSA and pathological characters of 2 groups (A and B)
Low risk group: PSA≤10, Gleason score≤6, TNM stage: ≤T2a, N0, M0, A: prostate cancer was detected only at the far lateral areas (lateral apex, mid-lobe and base-7, 8, 9, 10, 11, 12 sites), B: prostate cancer was detected at all sites, including the medial sites, PSA: prostate-specific antigen. *: statistical analysis by chi-squre test
Table 3
PSA distribution of 2 groups (A and B)
Low risk group: Gleason score≤6, TNM stage: ≤T2a, N0, M0, A: prostate cancer was detected only at the far lateral areas (lateral apex, mid-lobe and base-7, 8, 9, 10, 11, 12 sites), B: prostate cancer was detected at all sites, including the medial sites, PSA: prostate-specific antigen. *: statistical analysis by chi-squre test, †: statistical analysis by Fisher's exact test
References
1. Hodge KK, McNeal JE, Terris MK, Stamey TA. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol. 1989. 142:71–74.
2. Naughton CK, Smith DS, Humphrey PA, Catalona WJ, Keetch DW. Clinical and pathologic tumor characteristics of prostate cancer as a function of the number of biopsy core: a retrospective study. Urology. 1998. 52:808–813.
3. Levine MA, Ittman M, Melamed J, Lepor H. Two consecutive sets of transrectal ultrasound guided sextant biopsies of the prostate for the detection of prostate cancer. J Urol. 1998. 159:471–475.
4. Eskew LA, Bare RL, McCullough DL. Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J Urol. 1997. 157:199–202.
5. Stewart CS, Leibovich BC, Weaver AL, Lieber MN. Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies. J Urol. 2001. 166:86–91.
6. Babaian RJ, Toi A, Kamoi K, Troncoso P, Sweet J, Evans R, et al. A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy. J Urol. 2000. 163:152–157.
7. Presti JC Jr, Chang JJ, Bhargava V, Shinohara K. The optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsies: results of a prospective clinical trial. J Urol. 2000. 163:163–166.
8. Ravery V, Goldblatt L, Royer B, Blanc E, Toublan M, Bocon-Gibod L. Extensive biopsy protocol improves the detection rate of prostate cancer. J Urol. 2000. 164:393–396.
9. Norberg M, Egevad L, Holmberg L, Sparen P, Norlen BJ, Busch C. The sextant protocol for ultrasound-guided core biopsies of the prostate underestimates the presence of cancer. Urology. 1997. 50:562–566.
10. Yeo BG, Lee ES, Byun SS. Peripheral 10 sites prostate biopsy: is it really effective? Korean J Urol. 2003. 44:851–854.
11. Lee SB, Kim CS, Ahn H. Comparative analysis of sextant and extended prostate biopsy. Korean J Urol. 2004. 45:524–529.
12. Eskew LA, Woodruff RD, Bare RL, McCullough DL. Prostate cancer diagnosed by the 5 region biopsy method is significant disease. J Urol. 1998. 160:794–796.
13. Thomspson I, Thrasher JB, Aus G, Burnett AL, Canby-Hagino ED, Cookson MS, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol. 2007. 177:2106–2131.
14. Stamey TA. Editorial comment: systematic 5 region prostate biopsy for prostate cancer diagnosis. J Urol. 1997. 157:199.
15. Durkan GC, Sheikh N, Johnson P, Hildreth AJ, Greene DR. Improving prostate cancer detection with an extended-core transrectal ultrasonography-guided prostate biopsy protocol. BJU Int. 2002. 89:33–39.
16. Kim TB, Lee SE, Jeong H. The effectiveness of 12 core biopsy protocol according to prostate-specific antigen (PSA) level and prostate volume. Korean J Urol. 2006. 47:1166–1171.
17. Moon KH, Cheon SH, Kim CS. Systematic 10-site prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. Korean J Urol. 2000. 41:1178–1182.
18. Freedland SJ, Kane CJ, Amling CL, Aronson WJ, Presti JC Jr, Terris MK. A delay of radical prostatectomy and risk of biochemical progression in men with low risk prostate cancer. J Urol. 2006. 175:1298–1303.
19. Cintra ML, Billis A. Histologic grading of prostatic adenocarcinoma: intraobserver reproducibility of the Mostofi, Gleason, and Bocking grading systems. Int Urol Nephrol. 1991. 23:449–454.
20. Epstein JI, Pizov G, Walsh PC. Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer. 1993. 71:3582–3593.
21. Kim YJ, Chang IH, Gil MC, Hong SK, Byun SS, Lee SE. Concordance of Gleason scores between prostate needle biopsy and radical prostatectomy specimens according to the number of biopsy cores. Korean J Urol. 2006. 47:482–488.
22. Naughton CK, Ornstein DK, Smith DS, Catalona WJ. Pain and morbidity of transrectal ultrasound guided prostate biopsy: a prospective randomized trial of 6 versus 12 cores. J Urol. 2000. 163:168–171.
XML Download